Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

34.67 -0.24 (-0.69%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,218,740
Open 34.75
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 34.91
Today's Range 34.56 - 34.82
52wk Range 29.20 - 40.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-4.62%
-4.62%
1 Month
+10.66%
+10.66%
3 Month
+8.51%
+8.51%
6 Month
-4.31%
-4.31%
1 Year
-9.03%
-9.03%

More News

Read More
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
Via InvestorPlace
Exposures Product Safety
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Via Benzinga
Exposures Product Safety
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
Via MarketBeat
Exposures Product Safety
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Via Investor's Business Daily
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Via FinancialNewsMedia
Exposures Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
From Genentech
Via Business Wire
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Via Benzinga
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
Via The Motley Fool
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
From Genentech
Via Business Wire
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Via Benzinga
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
From Genentech
Via Business Wire
Can Ocugen Stock Keep Churning Higher?
Via The Motley Fool
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.